Impact of the Coronavirus Disease 2019 pandemic on neoadjuvant chemotherapy use in patients diagnosed with epithelial type ovarian cancer
DiscussionsOvarian cancer patients diagnosed in the COVID-19 pandemic were more likely to receive neoadjuvant chemotherapy than patients diagnosed before the pandemic. Future research on patient outcomes and trends in the post-pandemic period are warranted.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Coronavirus | COVID-19 | Electronic Medical Records (EMR) | Epidemiology | Epithelial Cancer | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Ovarian Cancer | Ovaries | Pandemics | Study | USA Health